Recent studies have shown that suppressing IgE- FcεRI crosslinking by blocking translation of FcεRI β-subunit or modulating splicing events and inducing exon skipping could be a potential therapeutic strategy as tested in a mouse model of allergic dermatitis (22). Here, FCER1A is linked to atopic eczema.